Renin-angiotensin system blockade prevents the increase in plasma transforming growth factor β1, and reduces proteinuria and kidney hypertrophy in the streptozotocin-diabetic rat

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 5, Issue 3, 2004, Pages 146-151

  Erman, Arie ^a,b   Veksler, Semyon ^a,b   Gafter, Uzi ^a,b   Boner, Geoffrey ^a,b   Wittenberg, Clara ^a,b   van Dijk, David Jonathan ^a,b  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

ACE I; ARB; Diabetis mellitus; Proteinuria; Renin angiotensin system; TGF 1

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; GLUCOSE; LOSARTAN; PROTEIN; STREPTOZOCIN; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETES MELLITUS; DOSE RESPONSE; ENZYME ACTIVITY; ENZYME INHIBITION; GLUCOSE BLOOD LEVEL; HORMONE INHIBITION; IN VITRO STUDY; IN VIVO STUDY; KIDNEY HYPERTROPHY; KIDNEY MASS; LONG TERM CARE; MALE; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEINURIA; RAT; RECEPTOR BLOCKING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; STREPTOZOCIN DIABETES; URINARY EXCRETION;

EID: 6444229856     PISSN: 14703203     EISSN: None     Source Type: Journal    
DOI: 10.3317/jraas.2004.032     Document Type: Article

References (37)

1. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Eng J Med 1993;329:1456-62.
2. Andersen S, Tarnow L, Rossing P, Hansen BV, Parving HH. Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy. Kidney Int 2000; 57 601-6.
3. Brenner BM, Cooper ME, de Zeeuv D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type II diabetes and nephropathy. N Engl J Med 2001;345:861-9.
4. Anderson S, Jung FF, Ingelfinger JR. Renin-angiotensin system in diabetic rats: functional, immunochemical and molecular biologic correlations. Am J Physiol 1993;265:F477-F486.
5. Remuzzi A, Perico N, Amuchastegui CS et al. Short and long-term effect of angiotensin II receptor blockade in rats with experimental diabetes. J Am Soc Nephrol 1993;4:40-9.
6. Natif N, Sclerovsky-Binjaminov F, van Dijk DJ, Gafter U, Boner G, Erman A. Insulin and losartan reduce proteinuria and kidney hypertrophy in the pregnant diabetic rat. J Lab Clin Med 2003; 142:167-72.
7. Jacobsen P, Andersen S, Jensen BR, Parving HH. Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy. J Am Soc Nephrol 2003;14:992-9.
8. Agarwal R. Add-on angiotensin receptor blockade with maximized ACE inhibition. Kidney Int 2002;59:2282-9.
9. Mogensen CE, Neldam S, Tikkanen I et al. Randomized controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the Candesartan and Lisinopril Microalbuminuria (CALM) Study. BMJ 2000;321:1440-4.
10. Noble NA, Border WA. Angiotensin II in renal fibrosis: Should TGFβ rather than blood pressure be the therapeutic target? Sem Nephrol 1997;5:455-6.
11. Ibrahim H, Hostetter TH. Aldosterone in renal disease. Curr Opinion Nephrol Hypertens 2003;12:159-64.
12. Peters H, Ritz E. Dosing angiotensin II blockers-beyond blood pressure. Nephrol Dial Transplant 1999;14:2568-70.
13. Yamamoto T, Noble NA, Cohen AH et al. Expression of transforming growth factor β isoforms in human glomerular diseases. Kidney Int 1996;49:461-9.
14. Hill C, Flyvbjerg A, Gronbaek H et al. The renal expression of transforming growth factor β, isoforms and their receptors in acute and chronic experimental diabetes in rats. Endocrinol 2000;141:1196-208.
15. Volpini RA, da Silva CG, Costa RS, Coimbra TM. Effect of enalapril and losartan on the events that precede diabetic nephropathy in rats. Diabetes Metab Res Rev 2003;19:43-51.
16. Agarwai R, Siva S, Dunn SR, Sharma K. Add-on angiotensin II receptor blockade lowers urinary transforming growth factor-β levels. Am J Kid Dis 2002;39:486-92.
17. Benigni A, Zoja C, Corna D et al. Add-on anti-TGFβ, antibody to ACE inhibitor arrests progressive diabetic nephropathy in the rat. J Am Soc Nephrol 2003;14:1816-24.
18. Erman A, van Dijk DJ, Chen-Gal B et al. Angiotensin converting enzyme activity in the serum, lung and kidney of diabetic rats. Eur J Clin Invest 1993;23:615-20.
19. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantity of protein utilizing of protein-dye binding. Anal Biochem 1976;72:248-54.
20. Ots M, Mackenzie HS, Troy JL, Rennke HG, Brenner BM. Effects of combination therapy with enalapril and losartan on the rate of progression of renal injury in rats with 5/6 renal mass ablation. J Am Soc Nephrol 1998;9:224-30.
21. Komine N, Khang S, Wead LM, Blanz RC, Gabbai FG. Effect of combining an ACE inhibitor and an angiotensin II receptor blocker on plasma and kidney tissue angiotensin II levels. Am J Kid Dis 2002;39:159-64.
22. Jacobsen P, Andersen S, Rossing K, Jensen BR, Parving HH. Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy. Kidney Int 2003; 63;1874-80.
23. Rabkin R, Shecter P, Dong Shi J, Boner G. Protein turnover in the hypertrophying kidney. Miner Electrol Metab 1996;22: 153-6.
24. Leehey DJ, Singh AK, Alavi N, Singa R. Role of angiotensin II in diabetic nephropathy. Kidney Int 2000;58(suppl 77):S93-S98.
25. Wolf G, Ziyadeh FN. Renal tubular hypertrophy induced by angiotensin II. Sem Nephrol 1997;17:448-54.
26. Andersen S, Tarnow L, Rossing P, Hansen BV, Parving HH. Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy. Kidney Int 2000; 57 601-6.
27. Thurman JM, Schrier RW. Comparative effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on blood pressure and the kidney. Am J Med 2003; 114 588-98.
28. Ruiz-Ortega M, Gonzalez S, Seron D et al. ACE inhibition reduces proteinuria, glomerular lesions and extracellular matrix production in normotensive rat model of the immune complex nephritis. Kidney Int 1995;48:1778-91.
29. Itoh Y, Imamura S, Yamamoto K et al. Changes of endothelin in streptozotocin-induced diabetic rats: effects of an angiotensin converting enzyme inhibitor, enalapril maleate. J Endocrinol 2002;175:233-9.
30. Navar LG, Harrison-Bernard LM, Nishiyama A, Kobori H. Regulation of intrarenal angiotensin II in hypertension. Hypertension 2002;39[part 2]:316-22.
31. van Dijk DJ, Boner G, Erman A. Increased serum angiotensin-converting enzyme activity and plasma angiotensin II levels during pregnancy and postpartum in the diabetic rat. JRAAS 2002; 2:193-8.
32. Erman A, Winkler J, Chen-Gal B et al. Inhibition of angiotensin converting enzyme by ramipril in serum and tissue of man. J Hypertens 1991;9:1057-62.
33. Cushman DW, Wang FL, Fung WC et al. Comparison in vivo, ex vivo and in vitro of the actions of seven structurally diverse inhibitors of angiotensin converting enzyme. Br J Clin Pharmacol 1989;28:115S-131S.
34. Goetz RM, Holtz J. Enhanced angiotensin-converting enzyme activity and impaired endothelium-dependent vasodilation in aortae from hypertensive rats: evidence for a causal link. Clin Sci 1999; 97 165-74.
35. van Dijk DJ, Erman A, Erman T, Chen-Gal B, Sulkes J, Boner G. Increased serum angiotensin converting enzyme activity in type I insulin-dependent diabetes mellitus: its relation to metabolic control and diabetic complications. Eur J Clin Invest 1994; 24:463-7.
36. Sharma K, Eltayeb BO, McGowan TA et al. Captopril-induced reduction of serum levels of transforming growth factor-β1 correlates with long-term renoprotection in insulin-dependent diabetic patients. Am J Kid Dis 1999; 34:818-23.
37. Obata J, NakamuraT, Kuroyanagi R, Yosida Y, Guo D, Inagami T. Candesartan prevents the progression of glomerulosclerosis in genetic hypertensive rats. Kidney Int 1997; 63:S229-S231.